• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Irish America

Irish America

        • Who We Are
          • About Us
          • Irish America Team
        • The Lists
          • Business 100
          • Hall of Fame
          • Health and Life Sciences 50
          • Wall Street 50
        • Highlights
          • History
          • In This Issue
          • Music
          • Politics
          • Sports
          • Travel
        • Columns
          • First Word
          • Hibernia
          • Quote Unquote
          • Slainte
          • Those we Lost
          • What are you like?
          • Wild Irish Women
          • Window on The Past
  • Home
  • Who We Are
    • About This Magazine
    • Irish America Team
  • In This Issue
  • Hall of Fame
  • The Lists
    • Business 100
    • Hall of Fame
    • Health and Life Sciences 50
    • Wall Street 50
  • Archives
    • Magazine
    • Highlights
  • Travel
  • Events

New Cancer Drug May Skip Ireland

By Olivia O’Mahony, Editorial Assistant
August / September 2016

August 10, 2016 by 1 Comment

A groundbreaking new melanoma treatment is being rolled out to patients in the U.K., but may never reach those in Ireland. The National Pharmacoeconomics Centre (NCPE), an independent medicine cost advisory board, has recommended that the HSE does not make the Opdivo drug available through the public system due to uncertainty about its financial sustainability.
Research has proven that melanoma patients have a substantially longer life expectancy when taking Opdivo, which, unlike conventional chemotherapy, is administered by a drip. The drug was developed by Bristol Myers Squib, who told the NCPE that Opdivo’s net cost over the first five years will come to €17.6 million. This estimation is based on the drug’s usage being capped at a maximum of two years. However, the NCPE review group found insufficient evidence that the projected discontinuation point would hold true. Even following a revised gross budget submission from Bristol Myers Squib in 2015, the NCPE did not consider Opdivo cost-effective.
A spokeswoman for the HSE said that it was required to manage financial provisions for new medicines in a fair manner, with access being made available to as wide a range of new drugs as sustainably possible.
Opdivo will be reviewed by the National Cancer Control Program Technology Review Committee. If given a positive recommendation, it will be sent to the HSE Drugs Committee for the ultimate ruling on its funding. ♦

Reader Interactions

Comments

  1. Margaret Clifford says

    August 20, 2016 at 2:28 pm

    Very disappointed to read this article because this could have a future affect on out family!!!!

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Highlights

News
Articles and stories from Irish America.....
MORE

Hibernia
News from Ireland and happenings in Irish America.....
MORE

Those We Lost
Remembering some of the great Irish Americans who have passed.....
MORE

Slainte!
Discover Irish ancestry, predilections, and recipes.....
MORE

Photo Album
Irish America readers share the stories of their ancestors....
MORE

More Articles

  • <b>Hibernia: Honors</b>Hibernia: Honors
    Irish LGBT Rights Campaigner Honored In NYC A street in Queens, New York, has been named after B...
  • <b>Hibernia: News</b>Hibernia: News
    Dublin Second In Europe For Improving Air Quality Dublin has been named the second most improved...
  • <b>Hibernia: Sports</b>Hibernia: Sports
    Leona Maguire Is First Irish Golfer To Win The LPGA Leona Maguire has made history as the&nb...
  • <b>Hibernia: News From Ireland</b>Hibernia: News From Ireland
    Kerry Town Named Among Europe's Most Beautiful The scenic village of Kenmare, nestled on the...

Footer

Follow Us

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube

Subscribe

  • Subscribe
  • Give a Gift
  • Newsletter
  • Customer Service

Additional

  • Advertise
  • Contact
  • Terms of Use & Privacy Policy

Copyright © 2022 · IrishAmerica Child Theme on Genesis Framework · WordPress · Log in